2025
Liver Fibrosis and Cardiovascular Events
Nso N, Bookani K, Trimingham M, Orji R, Njei B, Balasubramanian S, Pursnani A. Liver Fibrosis and Cardiovascular Events. Southern Medical Journal 2025, 118: 19-25. PMID: 39753232, DOI: 10.14423/smj.0000000000001769.Peer-Reviewed Original ResearchConceptsLiver fibrosis scoresNonalcoholic fatty liver diseaseRisk of cardiovascular eventsNAFLD fibrosis scoreCardiovascular eventsAll-Cause MortalityFibrosis scoreLiver fibrosisSystematic reviewFibrosis-4Noninvasive liver fibrosis scoresLiver diseaseCardiovascular mortalityHigh risk of cardiovascular eventsNonalcoholic fatty liver disease fibrosis scoreRelevant prospective studiesSeverity of liver fibrosisNational Institutes of Health toolCardiovascular diseaseHigher liver fibrosis scoresSpectrum of cardiovascular diseasesFibrosis-4 scoreSeverity of fibrosisCardiovascular event occurrenceChronic liver disease
2022
Hepatic PEMT Expression Decreases with Increasing NAFLD Severity
Piras I, Raju A, Don J, Schork N, Gerhard G, DiStefano J. Hepatic PEMT Expression Decreases with Increasing NAFLD Severity. International Journal Of Molecular Sciences 2022, 23: 9296. PMID: 36012560, PMCID: PMC9409182, DOI: 10.3390/ijms23169296.Peer-Reviewed Original ResearchConceptsPhosphatidylethanolamine N-methyltransferaseNonalcoholic fatty liver diseaseFine-mapping analysisPostmenopausal womenIncreasing severity of NAFLDHepatic fibrosisHigh risk of nonalcoholic fatty liver diseaseIncreasing severity of fibrosisNonalcoholic fatty liver disease patientsSeverity of nonalcoholic fatty liver diseaseRisk of nonalcoholic fatty liver diseaseIncreasing severityNonalcoholic fatty liver disease severityCohort of patientsSeverity of fibrosisGenetic variantsAssociated with NAFLD riskProducts of phosphatidylcholineSpectrum of nonalcoholic fatty liver diseaseGene expressionNormal liver histologyPhosphatidylcholine synthesisFatty liver diseaseN-methyltransferaseNASH patients
2021
Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, Rounseville SP, Krafty RT, Wollin L, Sauler M, Hecker L. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. European Respiratory Journal 2021, 58: 2100759. PMID: 34531276, PMCID: PMC8613836, DOI: 10.1183/13993003.00759-2021.Peer-Reviewed Original ResearchConceptsEfficacy of nintedanibIdiopathic pulmonary fibrosisAged miceLung fibrosisPulmonary fibrosisElderly patientsLung functionPre-clinical efficacy studiesAged animal modelsIPF clinical trialsVital capacity declineAverage patient ageVehicle-treated miceVehicle-treated groupEffect of nintedanibSeverity of fibrosisDevelopment of fibrosisTotal lung collagenSimilar extentNintedanib treatmentLung injuryPatient ageIPF diagnosisClinical efficacyFibrosis severity
2019
Non‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham Study
Weinstein G, Davis‐Plourde K, Himali JJ, Zelber‐Sagi S, Beiser AS, Seshadri S. Non‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham Study. Liver International 2019, 39: 1713-1721. PMID: 31155826, PMCID: PMC6736704, DOI: 10.1111/liv.14161.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseNAFLD fibrosis scoreFatty liver diseaseCognitive functionAdvanced fibrosisFibrosis scoreLiver diseaseBrain healthLower riskPresence of NAFLDRelationship of NAFLDLiver fibrosis scoresExcessive alcohol intakeVisceral adipose tissueSeverity of fibrosisPoor cognitive functionMiddle-aged adultsExecutive functionCross-sectional relationshipNAFLD diagnosisCardiometabolic variablesAlcohol intakeFramingham StudyInsulin resistancePotential confounders
2004
Lack of Integrin α1β1 Leads to Severe Glomerulosclerosis after Glomerular Injury
Chen X, Moeckel G, Morrow JD, Cosgrove D, Harris RC, Fogo AB, Zent R, Pozzi A. Lack of Integrin α1β1 Leads to Severe Glomerulosclerosis after Glomerular Injury. American Journal Of Pathology 2004, 165: 617-630. PMID: 15277235, PMCID: PMC1618576, DOI: 10.1016/s0002-9440(10)63326-3.Peer-Reviewed Original ResearchConceptsSevere glomerulosclerosisGlomerular injuryIntegrin alpha1-null miceSeverity of fibrosisCollagen IV accumulationWild-type miceHost genetic susceptibilityMetabolism of collagenReactive oxygen species productionFibrotic lesionsIntegrin alpha1beta1Oxygen species productionAdriamycin treatmentMesangial cellsMatrix accumulationGenetic susceptibilityInjuryGlomerulosclerosisFibrosisCell proliferationROS productionSpecies productionROS synthesisIntegrin α1β1Mice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply